SGMOQ · Sangamo Therapeutics, Inc · Held by Funds
Substantial doubt about the company's ability to continue as a going concern.
“Our history of significant losses, negative cash flows from operations, negative working capital, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued.”View the 10-Q filed May 14, 2026
Registered funds — mutual funds, ETFs and closed-end funds — whose latest Form N-PORT portfolio report holds this exact listed security, matched by CUSIP. Each row is one fund position with its size, value and weight in that fund.
Fund Ownership of SGMOQ by Fund Type
Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026Index funds and index ETFs hold 0.39% of shares outstanding.
| Fund type | Of shares outstanding | Shares |
|---|---|---|
| Index funds | 0.17% | 712,200 |
| Index ETFs | 0.22% | 902,906 |
| Active ETFs | 0.00% | 0 |
| Active funds | 0.15% | 628,661 |
| Unclassified | 0.00% | 0 |
| All registered funds | 0.54% | 2,243,767 |
How fund types are measured
Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.
Funds holding SGMOQ
12 fund positions| Fund | Ticker | Balance | Value | % of Fund | Side | Reported | Open |
|---|---|---|---|---|---|---|---|
| Goldman Sachs Human Evolution ETF | — | 33,651 | $371,339 | 0.76% | Long | 2020-08-31 | |
| Kelly CRISPR & Gene Editing Technology ETF | — | 101,500 | $43,645 | 1.69% | Long | 2023-11-30 | |
| Defiance Nasdaq Junior Biotechnology ETF | — | 3,325 | $29,958 | 0.41% | Long | 2021-09-30 | |
| PGIM QMA Strategic Alpha Small-Cap Growth ETF | — | 2,735 | $27,104 | 0.18% | Long | 2021-08-31 | |
| ProShares UltraPro Nasdaq Biotechnology | — | 2,688 | $22,929 | 0.11% | Long | 2020-02-29 | |
| Nomura Healthcare Fund | — | 400,000 | $21,560 | 0.00% | Long | 2026-06-30 | |
| PGIM QMA Strategic Alpha Small-Cap Value ETF | — | 1,904 | $18,869 | 0.14% | Long | 2021-08-31 | |
| iShares Evolved U.S. Innovative Healthcare ETF | — | 3,476 | $14,912 | 0.04% | Long | 2022-07-31 | |
| VIP Disciplined Small Cap Portfolio | — | 220,038 | $11,860 | 0.00% | Long | 2026-06-30 | |
| Principal Healthcare Innovators ETF | — | 13,692 | $4,906 | 0.03% | Long | 2024-06-30 | |
| iShares Factors US Small Blend Style ETF | — | 278 | $3,328 | 0.04% | Long | 2021-06-30 | |
| Guggenheim Active Allocation Fund | GUG | 1,415 | $308 | 0.00% | Long | 2026-05-29 |